Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
05-25-2017, 09:44 AM
GW Pharma details an impressive PhIII case for a cannabis-based drug for severe epilepsy as it preps an NDAby <span><span><a data-ipb="nomediaparse" href="https://endpts.com/about/#John%20Carroll">John Carroll</a><a data-ipb="nomediaparse" href="mailto:john@endpointsnews.com?subject=Regarding%20your%20article&body=Hello%2C%20John%20Carroll%0AI%27m%20writing%20regarding%20article%20GW%20Pharma%20details%20an%20impressive%20PhIII%20case%20for%20a%20cannabis-based%20drug%20for%20severe%20epilepsy%20as%20it%20preps%20an%20NDA%20which%20is%20located%20at%20https%3A%2F%2Fendpts.com%2Fgw-pharma-details-an-impressive-phiii-case-for-a-cannabis-based-drug-for-severe-epilepsy-as-it-preps-an-nda%0A" title="Contact author"></a></span></span> on
May 25, 2017
GW Pharmaceuticals lined up a straight shot at a key approval for Epidiolex today, publishing its impressive Phase III data for a severe form of childhood epilepsy which inspired a blockbuster forecast for the cannabis-based therapy.
GW announced last spring that Epidiolex a liquid therapy using purified cannabadiol triggered a mean reduction in convulsive seizures of 39% among treatment-resistant patients with Dravet syndrome, compared to only 13% among the placebo group. A report published in The New England Journal of Medicine adds today that 43% of the drug group had a mean drop of 50% or more compared to 27% in the placebo group. And 5% stopped having seizures, with none in the placebo arm doing as well.......
<a data-ipb="nomediaparse" href="https://endpts.com/gw-pharma-details-an-impressive-phiii-case-for-a-cannabis-based-drug-for-severe-epilepsy-as-it-preps-an-nda/">https://endpts.com/gw-pharma-details-an-impressive-phiii-case-for-a-cannabis-based-drug-for-severe-epilepsy-as-it-preps-an-nda/</a>
May 25, 2017
GW Pharmaceuticals lined up a straight shot at a key approval for Epidiolex today, publishing its impressive Phase III data for a severe form of childhood epilepsy which inspired a blockbuster forecast for the cannabis-based therapy.
GW announced last spring that Epidiolex a liquid therapy using purified cannabadiol triggered a mean reduction in convulsive seizures of 39% among treatment-resistant patients with Dravet syndrome, compared to only 13% among the placebo group. A report published in The New England Journal of Medicine adds today that 43% of the drug group had a mean drop of 50% or more compared to 27% in the placebo group. And 5% stopped having seizures, with none in the placebo arm doing as well.......
<a data-ipb="nomediaparse" href="https://endpts.com/gw-pharma-details-an-impressive-phiii-case-for-a-cannabis-based-drug-for-severe-epilepsy-as-it-preps-an-nda/">https://endpts.com/gw-pharma-details-an-impressive-phiii-case-for-a-cannabis-based-drug-for-severe-epilepsy-as-it-preps-an-nda/</a>